Question from Deputy Ken O’Flynn - PQ 38847-26
Deputy O'Flynn asked about the reimbursement consideration for omaveloxolone (skyclarys). Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked about the reimbursement consideration for omaveloxolone (skyclarys). Read the HSE response.
Deputy O'Flynn asked if the HSE has a national medicines waste reduction strategy. Read the HSE response.
Deputy O'Flynn asked if the HSE records the quantity and estimated value of unused or expired medicines returned to community pharmacies. Read the HSE response.
Deputy O'Flynn asked about the annual cost to the Exchequer of unused, expired, uncollected, or otherwise wasted medicines. Read the HSE response.
Deputy O'Flynn asked about the policy measures that are currently in place to reduce avoidable medicines waste. Read the HSE response.
Deputy O'Flynn asked about vacancy levels within Children's Disability Network Teams (CDNTs). Read the HSE response.
Deputy O'Meara asked when will medical cards be issued to those who have applied under the Supports for Survivors of Residential Institutional Abuse Act 2025.
Deputy O'Flynn asked how are reimbursement decisions for high-cost orphan medicines are financially planned. Read the HSE response.
Deputy O'Flynn asked if a national clinical prioritisation framework exists for patients awaiting knee replacement. Read the HSE response.
Deputy O'Flynn asked whether any national framework exists governing audit of overseas referrals funded through TAS. Read the HSE response.